The UK-Israeli €378M Small-Molecule Offensive Against Migraines

26/11/2015 - 2 minutes

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines.

teva_heptares_sosei_migraines_israel_dealjpgThe pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity (often an early indication one is on the way), nausea and a throbbing pain behind the eyes and in the temples.

Heptares Therapeutics is a UK biotech which looks to treat such a condition, with a broad neurological drug portfolio to include other indications like Alzheimer’s, Schizophrenia and ADHD. Founded by Fiona Marshall (one of our Top 10 UK Women in Biotech), she now serves as a CSO to Japanese Big boss Sosei, which wholly acquired Heptares earlier this year in a €373M deal. Other partners include Takeda, AstraZeneca, Cubist Pharma (US), MorphoSys and MedImmune.

What makes Heptares such an attractive partner is their GPCR platform and its extensive number of applications and targets available (which are well explained on their website –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!